Literature DB >> 28454472

Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells.

Hyun Gyo Lee1, Won Jin Park2, So Jin Shin2, Sang Hoon Kwon2, Soon Do Cha2, Young Ho Seo3, Ju Hui Jeong3, Ji Yoon Lee1, Chi Heum Cho1,2.   

Abstract

The aim of the present study was to evaluate the in vitro effect of a heat shock protein (Hsp)90 inhibitor, SY-016, on the paclitaxel (PTX)-resistant human ovarian cancer cell line OVCAR-3PTX, and explore its mechanism of apoptosis. In the present study, SY-016 was used in combination with PTX to determine its effect on the cell proliferation and apoptosis of OVCAR-3PTX cells. The drug-resistant tumor cells were established in vitro by stepwise sequential exposure to increasing concentrations of PTX. The cell viability and cell cycle distribution were measured by MTT assay and flow cytometric analysis, respectively. The induction of apoptosis was measured by caspase-3 activity, DNA fragmentation and western blot analyses. The cell viability significantly decreased following treatment with PTX and SY-016 as compared with either drug alone. The DNA fragmentation assay revealed an induction of apoptosis. The results from the flow cytometric analysis revealed an increase in the percentage of cells in the G2/M phase. Downregulation of B-cell lymphoma (Bcl)-2, X-linked inhibitor of apoptosis protein, survivin, Akt, nuclear factor-κB and cyclin-dependent kinase 4, as well as upregulation of Bcl-2-associated X protein, were observed. SY-016 may contribute to the induction of apoptosis in OVCAR-3PTX cells. These results suggest that SY-016 in combination with PTX may be a beneficial chemotherapeutic strategy, particularly in patients with tumors refractory to PTX.

Entities:  

Keywords:  Hsp90; apoptosis; inhibitor; ovarian cancer; resistance

Year:  2017        PMID: 28454472      PMCID: PMC5403452          DOI: 10.3892/ol.2017.5794

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice.

Authors:  Lin Jin; Chuan-Le Xiao; Chun-Hua Lu; Min Xia; Guo-Wen Xing; Sheng Xiong; Qiu-Ying Liu; Hui Liu; Yi-Cheng Li; Feng Ge; Qing-Duan Wang; Qing-Yu He; Yi-Fei Wang
Journal:  FEBS Lett       Date:  2009-05-08       Impact factor: 4.124

2.  Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin.

Authors:  Zhi-Jun Sun; Gang Chen; Xiang Hu; Wei Zhang; Yang Liu; Ling-Xin Zhu; Qian Zhou; Yi-Fang Zhao
Journal:  Apoptosis       Date:  2010-07       Impact factor: 4.677

Review 3.  HSP90 and the chaperoning of cancer.

Authors:  Luke Whitesell; Susan L Lindquist
Journal:  Nat Rev Cancer       Date:  2005-10       Impact factor: 60.716

4.  Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Authors:  Eiji Oki; Hideo Baba; Eriko Tokunaga; Toshihiko Nakamura; Naoyuki Ueda; Motonori Futatsugi; Kohjiro Mashino; Manabu Yamamoto; Masahiko Ikebe; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Cancer       Date:  2005-11-10       Impact factor: 7.396

5.  Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.

Authors:  K Mayerhofer; E Kucera; H Zeisler; P Speiser; A Reinthaller; P Sevelda
Journal:  Gynecol Oncol       Date:  1997-01       Impact factor: 5.482

6.  Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Authors:  Zev A Wainberg; Adrian Anghel; Amy M Rogers; Amrita J Desai; Ondrej Kalous; Dylan Conklin; Raul Ayala; Neil A O'Brien; Cornelia Quadt; Mikhail Akimov; Dennis J Slamon; Richard S Finn
Journal:  Mol Cancer Ther       Date:  2013-02-08       Impact factor: 6.261

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mikio Terauchi; Mamoru Yamashita; Kazuhiko Ino; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Int J Oncol       Date:  2007-08       Impact factor: 5.650

9.  Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

Authors:  David A Proia; Jim Sang; Suqin He; Donald L Smith; Manuel Sequeira; Chaohua Zhang; Yuan Liu; Shuxia Ye; Dan Zhou; Ronald K Blackman; Kevin P Foley; Keizo Koya; Yumiko Wada
Journal:  Invest New Drugs       Date:  2012-01-10       Impact factor: 3.850

10.  Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines.

Authors:  Panagiotis K Karkoulis; Dimitrios J Stravopodis; Eumorphia G Konstantakou; Gerassimos E Voutsinas
Journal:  Cancer Cell Int       Date:  2013-02-08       Impact factor: 5.722

View more
  2 in total

1.  KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis.

Authors:  Shaoshan Yang; Xiaoli Ren; Yunshi Liang; Yongrong Yan; Yangshu Zhou; Jinlong Hu; Zhizhi Wang; Fuyao Song; Feifei Wang; Wangjun Liao; Wenting Liao; Yanqing Ding; Li Liang
Journal:  Oncogene       Date:  2019-09-02       Impact factor: 9.867

2.  Quinalizarin Induces Apoptosis through Reactive Oxygen Species (ROS)-Mediated Mitogen-Activated Protein Kinase (MAPK) and Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathways in Colorectal Cancer Cells.

Authors:  Ling-Qi Meng; Yue Wang; Ying-Hua Luo; Xian-Ji Piao; Chang Liu; Yue Wang; Yi Zhang; Jia-Ru Wang; Hao Wang; Wan-Ting Xu; Yang Liu; Yi-Qin Wu; Hu-Nan Sun; Ying-Hao Han; Mei-Hua Jin; Gui-Nan Shen; Nan-Zhu Fang; Cheng-Hao Jin
Journal:  Med Sci Monit       Date:  2018-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.